COVID-19 Information Center

Transmission electron microscopic image of an isolate from a case of coronavirus disease (COVID-19)
  • Coronavirus disease

COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) with safety of associates and patients globally as our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.

Novartis response to COVID-19

In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus disease pandemic.

Read More

Latest news

Study suggests there may be two stages of fatal lung disease in COVID-19

NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.

Read More

Information update about the Novartis CAN-COVID trial

The CAN-COVID clinical trial has been one of the ways Novartis is drawing on its global resources and scientific expertise in response to the COVID-19 pandemic.

Learn More

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19.

Read More

COVID-19 update at Q3 2020 Financial Results (Video)

Novartis CEO Vas Narasimhan comments on our efforts to combat COVID-19 at Q3 2020 Financial Results.

COVID-19 Update

Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique

Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.

Learn More

Choice with Responsibility: Reimagining how we work

Novartis now offers associates the choice to decide how, when and where they work within their country of employment to create the greatest impact for their role while taking personal responsibility to inform managers and align with teammates for effective collaboration, based on the nature of their work.

Read More

Our industry is at an inflection point. Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges

Read More

Sandoz responds to increased demand for antibiotics and other essential medicines for patients during COVID-19

Read More

  • Woman looking at an Ipad in a waiting room

    Patients and Caregivers

    Novartis is working to ensure supply of our medicines, enhance virtual services, protect the integrity of clinical trials and support patient organizations during the coronavirus disease (COVID-19) pandemic.

  • Doctors washing their hands

    Healthcare Professionals

    Novartis is working closely with healthcare professionals during the coronavirus disease pandemic. We are embracing new ways of working and have rapidly scaled up multichannel engagement.

  • Businessman with digital tablet

    Investors and Shareholders

    Novartis is regularly updating our Investor and Shareholder communities on the impact of coronavirus disease (COVID-19) and our response.

  • Business people working on a computer

    Job candidates

    Novartis is supporting candidates during the coronavirus disease (COVID-19) outbreak. During this time interviews will continue as planned and, where appropriate, will be switched to virtual interviews using readily available technology.

  • Man preparing a package


    Novartis is providing suppliers with recommended good practices guidance during the coronavirus disease (COVID-19) pandemic based on the most up-to-date World Health Organization (WHO) technical information.

  • Grey and white world map

    COVID-19 country resources

    Novartis provides country-specific information about coronavirus disease (COVID-19) in local languages.

Containing COVID-19 to serve patient needs

The coronavirus crisis has not only challenged the medical community to seek new treatments and vaccines. Keeping up with the production of existing drugs is equally challenging. Novartis has taken a series of measures to maintain production levels and serve millions of patients.

Read More

Ensuring medicine supply to patients during COVID-19

Read how two sites within the Novartis Technical Operations (NTO) network ensured business continuity at scale and speed in the midst of the COVID-19 pandemic.

Learn More

Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

Learn More

Novartis COVID-19 Stories

Read how Novartis is approaching the pandemic through the eyes of its associates.

Learn More

Novartis COVID-19 Response Fund

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

Learn More

Research and collaborations

EMG Gold Podcast

Pierre Bourdage, Global Head of Biopharmaceuticals at Sandoz, provides insight into the state and future of the biosimilars market and discusses how to adapt to ‘the new normal’.

How COVID-19 is reshaping the global healthcare ecosystem

On Bloomberg Live, Novartis CEO Vas Narasimhan shares insights on the importance of collaboration during COVID-19.

Watch Video

Leader perspectives during COVID-19

A mini-video-series in which Novartis leaders connect on video calls to discuss some of the biggest questions for healthcare as we navigate the global pandemic.

Watch Videos